A novel disialoganglioside (IV3NeuAcIII6NeuAcLc4) of human adenocarcinoma and the monoclonal antibody (FH9) defining this disialosyl structure.
This ganglioside is highly immunogenic, and immunization of mice with this disialoganglioside fraction coated on Salmonella minnesota followed by fusion of immunized spleen cells with mouse myeloma and selection of the hybridoma by positive reactivity with the purified disialoganglioside resulted in the establishment of a hybridoma secreting immunoglobulin G2a antibody FH9 that reacts specifically with the ganglioside antigen above but not with monosialosyllactotetraosylceramide I (IV3NeuAcLc4), monosialosyllactotetraosylceramide II (III6NeuAcLc4), or any other gangliosides tested.
D000230:Adenocarcinoma / Q000032:analysis*; D000911:Antibodies, Monoclonal; D002236:Carbohydrate Conformation; D002240:Carbohydrate Sequence; D002460:Cell Line; D002851:Chromatography, High Pressure Liquid; D002855:Chromatography, Thin Layer; D003110:Colonic Neoplasms / Q000032:analysis*; D004910:Erythrocyte Membrane / Q000032:analysis; D005732:Gangliosides / Q000276:immunology / Q000302:isolation & purification*; D006801:Humans; D008113:Liver Neoplasms / Q000032:analysis / Q000556:secondary*; D013058:Mass Spectrometry; D019158:N-Acetylneuraminic Acid; D012794:Sialic Acids / Q000032:analysis
D000911:Antibodies, Monoclonal; D005732:Gangliosides; D012794:Sialic Acids; D019158:N-Acetylneuraminic Acid